DGAP-News

ERYTECH PHARMA SA: Business Update and Financial Results for the First Half of 2014

DGAP-News: ERYTECH PHARMA SA / Key word(s): Half Year Results
ERYTECH PHARMA SA: Business Update and Financial Results for the First
Half of 2014

02.09.2014 / 18:00

---------------------------------------------------------------------

ERYTECH Business Update and Financial Results for the First Half of 2014

- Clinical trials on track and two new studies started

- Shareholder base further internationalized

- Solid cash balance


Lyon (France), September 2nd, 2014 - ERYTECH (Euronext Paris: FR0011471135
- ERYP), the French biopharmaceutical company that develops innovative
'tumor starvation' treatments for acute leukemia and other oncology
indications with unmet medical needs, provides a business update and
reports its financial results for the period ending June 30, 2014.

Business Highlights

- Phase III clinical study in Acute Lymphoblastic Leukemia (ALL) on track
for results early Q4

- International sites opened in Phase IIb Acute Myeloid Leukemia (AML)
study and positive Data Safety Monitoring Board (DSMB) assessment after
first 60 patients

- Phase II study launched in pancreatic cancer; first patient enrolled

- Phase I study in ALL launched in the USA; first patient enrolled

- Orphan drug designation granted to ERY-ASP in AML in the USA

- New oncology product candidate added (ERY-MET) and preclinical
development programs on track

- IP portfolio reinforced

- Board of directors strengthened with two new independent members

Financial Highlights

- Shareholder base further internationalized after successful share
replacement operation

- Net loss reduced and operating costs maintained notwithstanding
increased activity level

- Cash balance of EUR 12.3 million on June 30, 2014

Upcoming Milestones

- Results of European Phase III ALL study

- DSMB analysis for safety and futility in Phase IIb AML study

- First DSMB update on Phase II pancreas cancer study

"ERYTECH has made important progress during the first half of 2014. We have
advanced our clinical trials in acute leukemia according to plan and we
have made substantial headway in broadening our scope in solid tumors. We
are also advancing our preclinical pipeline with new products in oncology.
In addition we were able to strengthen our shareholder structure, with
additional specialized investors in the US and Europe, as well as our
board, with two new independent directors.", commented Gil Beyen, Chairman
and Chief Executive Officer of ERYTECH.